The article by Chirumbolo et al [1], provides comprehensive insight into the role of lipid enriched diet in the prevention of cancer by acting as modulatory signalling molecules. The ketogenic diet (KD) is a high fat and low carbohydrate diet that produces ketone bodies by mimicking starvation [2]. Obesity is associated with a significant increased risk of progression to high-grade prostate cancer (PCa) [2]. However, the KD significantly improves weight loss [2], and might mitigate tumour progression in patients with metastatic PCa.
The KD has been revealed to increase the effectiveness of radio/chemotherapy in vivo [2]. The KD mitigate oxidative stress and improve the endogenous antioxidant defense system [2]. D-β-hydroxybutyrate (βHB), a ketone body synthesized in the liver through the metabolism of fatty acids, is an endogenous inhibitor of class I histone deacetylases (HDACs) [3]. Class I HDACs inhibitors have been revealed to inhibit PCa proliferation in animal models [3]. βHB supplementation increased histone acetylation in mouse tissues [3]. Inhibition of HDAC by βHB was associated with changes in transcription, in the genes encoding oxidative stress resistance factors (Forkhead box class O 3a and Metallothionein 2) [3]. Moreover, administration of βHB in mice offered significant protection against oxidative stress, via upregulation of the antioxidant defense mechanisms [3].
βHB supplementation decreased tumor cell proliferation, viability and prolonged the survival of mice with metastatic cancer, via the Warburg effect [4]. The Warburg effect encompasses a vital weakness of cancer cells, pertaining to cancer cells dependence on excess glucose for survival and proliferation, which is prominent in metastatic cells [4]. Interestingly, PCa cells switch to the Warburg effect only in the metastatic stage [5], and ketone bodies inhibit glycolysis, consequently reducing the main pathway of energy production for metastatic cancer cells [4]. Moreover, cancer cells do not utilize ketones effectively for energy production, because of mitochondrial dysfunction [4].
In conclusion, metastatic PCa cells may not efficiently utilize ketone bodies for energy production. Moreover, the KG may slow down the proliferation of PCa cells, and consequently prevent metastasis. However, further preclinical, and clinical studies are needed to substantiate the effects of ketone bodies on the proliferation of metastatic PCa cells.
Notes
Conflict of Interest:The authors have nothing to disclose.
1. Chirumbolo S. Oxidative stress, nutrition and cancer: friends or foes? World J Mens Health 2021;39:19–30.
2. Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Kofler B. Ketogenic diet in the treatment of cancer - where do we stand? Mol Metab 2020;33:102–121.
3. Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013;339:211–214.
4. Poff AM, Ari C, Arnold P, Seyfried TN, D'Agostino DP. Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. Int J Cancer 2014;135:1711–1720.
5. Cutruzzolà F, Giardina G, Marani M, Macone A, Paiardini A, Rinaldo S, et al. Glucose metabolism in the progression of prostate cancer. Front Physiol 2017;8:97.
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Correspondence to: Chidiebere Emmanuel Okechukwu. Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy. Tel: +39-3249908039, Fax: +39-3510408450, Email: [email protected]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2022. This work is published under http://creativecommons.org/licenses/by-nc/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Inhibition of HDAC by βHB was associated with changes in transcription, in the genes encoding oxidative stress resistance factors (Forkhead box class O 3a and Metallothionein 2) [3]. [...]administration of βHB in mice offered significant protection against oxidative stress, via upregulation of the antioxidant defense mechanisms [3]. βHB supplementation decreased tumor cell proliferation, viability and prolonged the survival of mice with metastatic cancer, via the Warburg effect [4]. Interestingly, PCa cells switch to the Warburg effect only in the metastatic stage [5], and ketone bodies inhibit glycolysis, consequently reducing the main pathway of energy production for metastatic cancer cells [4]. [...]cancer cells do not utilize ketones effectively for energy production, because of mitochondrial dysfunction [4]. [...]metastatic PCa cells may not efficiently utilize ketone bodies for energy production.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer